Piper Sandler Comments on Gilead Sciences, Inc.’s Q4 2021 Earnings (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) – Piper Sandler decreased their Q4 2021 earnings per share estimates for Gilead Sciences in a report released on Monday, September 14th. Piper Sandler analyst T. Van. Buren now forecasts that the biopharmaceutical company will post earnings per share of $1.75 for the quarter, down from their previous estimate of $1.80. Piper Sandler has a “Overweight” rating and a $83.00 price objective on the stock. Piper Sandler also issued estimates for Gilead Sciences’ FY2022 earnings at $8.15 EPS, FY2023 earnings at $8.70 EPS and FY2024 earnings at $10.60 EPS.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.46). Gilead Sciences had a positive return on equity of 33.59% and a negative net margin of 1.16%. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.24 billion.
Gilead Sciences stock opened at $66.20 on Wednesday. The company has a quick ratio of 2.23, a current ratio of 2.33 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $83.00 billion, a P/E ratio of -275.82, a PEG ratio of 0.67 and a beta of 0.56. The stock’s 50 day moving average is $67.74 and its 200 day moving average is $73.87. Gilead Sciences has a twelve month low of $60.89 and a twelve month high of $85.97.
Hedge funds have recently modified their holdings of the business. Laurel Wealth Advisors LLC increased its stake in Gilead Sciences by 225.0% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 325 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 225 shares in the last quarter. Bainco International Investors purchased a new position in shares of Gilead Sciences during the first quarter valued at about $29,000. Global Wealth Management Investment Advisory Inc. grew its position in shares of Gilead Sciences by 66.5% during the second quarter. Global Wealth Management Investment Advisory Inc. now owns 388 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 155 shares in the last quarter. RMR Wealth Builders purchased a new position in shares of Gilead Sciences during the second quarter valued at about $30,000. Finally, Pacific Center for Financial Services grew its position in Gilead Sciences by 130.5% in the second quarter. Pacific Center for Financial Services now owns 484 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 274 shares in the last quarter. Institutional investors and hedge funds own 77.87% of the company’s stock.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a $0.68 dividend. The ex-dividend date is Monday, September 14th. This represents a $2.72 dividend on an annualized basis and a yield of 4.11%. Gilead Sciences’s payout ratio is presently 44.30%.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: Dividend Reinvestment Plan (DRIP)
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.